Controversies in the treatment of plasma cell myeloma
Postgraduate Medical JournalPublished 1 February 1985Open access
Daniel E. Bergsagel
Citations26
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Since there is no evidence that treatment benefits asymptomatic patients with benign monoclonal gammopathy, or stable smouldering myeloma, there is general agreement that only patients with progressive, symptomatic disease should be treated.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
New England Journal of MedicineEffective Treatment of Advanced Multiple Myeloma Refractory to Alkylating Agents
654 Citations1984Bart Barlogie, Lon Smith +1 more
Rapid and marked tumor-mass reduction was noted in 14 of 20 patients whose disease was resistant to alkylating agents and in 3 of 9 patients with additional resistance to doxorubicin--a result far superior to those in previous trials with similar patients.
New England Journal of MedicineThe Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute Leukemia
377 Citations1979Daniel E. Bergsagel, A Bailey +4 more
It is concluded that the combination of the four drugs is not better than melphalen and prednisone for inducing responses or prolonging the survival of patients with myeloma.
The American Journal of MedicineImproved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol
220 Citations1977Delvyn C. Case, Burton J. Lee +1 more
It appears that survival time in patients treated with M-2 will be significantly longer than in the earlier group treated at this center with melphalan and prednisone alone.
CancerCombination chemotherapy for multiple myeloma
210 Citations1972Raymond Alexanian, John D. Bonnet +6 more
Results support the value of combination chemotherapy with melphalan‐prednisone‐procarbazine for remission induction in patients with multiple myeloma.
Journal of neurosurgeryThe neurosurgical management of spinal metastases causing cord and cauda equina compression
174 Citations1978Kenneth E. Livingston, Richard G. Perrin
Positive approach and aggressive management in this problem can achieve results superior to those generally reflected in the literature, and effective pain relief in 70% of the patients.
Journal of Clinical OncologyAlternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study.
155 Citations1983S. E. Salmon, Arthur Haut +5 more
The use of aggressive multiagent chemotherapy for remission induction in patients with advanced-stage multiple myeloma is supported, with a significantly higher proportion of patients achieving at least 75% tumor mass regression with alternating combinations.
Clinical Orthopaedics and Related ResearchPyrophosphate and Diphosphonates in Skeletal Metabolism
140 Citations1975R.G.G. Russell, H. Fleisch
The diphosphonate, disodium ethane-1-hydroxy-1,1-diph phosphonate (EHDP) has been shown in clinical studies to be effective against ectopic calcification particularly in myositis ossificans progressiva and in disorders of increased bone resorption such as Paget's diseases and some types of osteoporosis.
BloodImproved survival of increased-risk myeloma patients on combined triple- alkylating-agent therapy: a study of the CALGB
97 Citations1979Harley Jb, TF Pajak +5 more
BloodUnmaintained remissions in multiple myeloma
93 Citations1978Raymond Alexanian, E. A. Gehan +3 more
Results supported the long-term evaluation without chemotherapy of selected patients with low numbers of plasma cells after treatment who were likely to experience long durations of disease stability and respond again to retreatment with melphalan-prednisone.
CancerChemotherapy for multiple myeloma
90 Citations1984Raymond Alexanian, Robert Dreicer
Results supported the utility of unmaintained remission follow‐up in selected patients with marked reductions in myeloma cell mass and showed that the addition of levamisole during remission maintenance did not improve survival time.
BloodPrednisone pulse therapy for refractory myeloma
84 Citations1983Raymond Alexanian, BS Yap +1 more
The utility of vindesine and a frequent prednisone schedule with increased doxorubicin dose in patients with advanced and resistant multiple myeloma was supported, and remissions were of excellent quality and survival was prolonged significantly.
BloodPrednisone pulse therapy for refractory myeloma
81 Citations1983Raymond Alexanian, BS Yap +1 more
The utility of vindesine and a frequent prednisone schedule with increased doxorubicin dose in patients with advanced and resistant multiple myeloma was supported, and remissions were of excellent quality and survival was prolonged significantly.
Acta HaematologicaIdentical Twin Marrow Transplantation in Multiple Myeloma
68 Citations2009Elliott F. Osserman, Leonard B. DiRe +4 more
New England Journal of MedicineMultiple-Myeloma Bone Disease
68 Citations1975Robert A. Kyle, Jenifer Jowsey +2 more
Fluoride calcium should be considered a useful adjunct in the treatment for multiple myeloma and its determinations proved insensitive for detection of skeletal changes.
The Journal of Clinical Endocrinology & MetabolismSome Results of the Effect of Fluoride on Bone Tissue in Osteoporosis
63 Citations1968Jenifer Jowsey, Robert Schenk +1 more
Bone biopsies taken after 7 to 24 months of therapy show that the effect of fluoride on bone tissue appears to be stimulation of new bone formation, although the new bone is largely uncalcified.
British Journal of HaematologyLong‐term survival in myelomatosis; A REPORT TO THE MRC WORKING PARTY ON LEUKAEMIA IN ADULTS
53 Citations1982Robert Buckman, Jack Cuzick +1 more
In this series, the chance of a patient surviving 5 years was strongly related to the haemoglobin, blood urea concentration (BUC) and performance status at presentation, and other features, including paraprotein levels, type of heavy or light chain, bone lesions and recovery of polyclonal immunoglobulin added little useful information.
New England Journal of MedicineInduction of Subacute Skeletal Fluorosis in a Case of Multiple Myeloma
51 Citations1964Phin Cohen, Frank H. Gardner
Although anemia and bone pain have been ameliorated in many cases in which any one of these drugs have been given, none achieve the therapeutic effectiveness of nitrogen mustard derivatives in the .
New England Journal of MedicineIneffectiveness of Fluoride Therapy in Multiple Myeloma
51 Citations1972John B. Harley, Albert Schilling +2 more
There is suggestive evidence that the production of fluorosis may be detrimental to the clinical course of a patient with multiple myeloma.
Archives of Internal MedicineTreatment of Plasma Cell Myeloma With Cytotoxic Agents
49 Citations1975Daniel E. Bergsagel
Forty-five patients with kappa- and 36 with lambda-light-chain disease showed no differences in frequency of amyloidosis, renal failure, response to treatment, or survival after treatment with alkylating agents.
Journal of Clinical OncologyA randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
32 Citations1984S Pavlovsky, J Saslavsky +8 more
No significant difference has been found between the two treatment schedules in terms of response rate and survival time, in any stage of disease.
Journal of Clinical OncologyProgress in the treatment of plasma cell myeloma?
25 Citations1983Daniel E. Bergsagel
PubMedPhase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
23 Citations1982Neil Abramson, Paul R. Lurie +4 more
A prospective randomized trial in patients with previously untreated multiple myeloma was performed comparing carmustine, cyclophosphamide, and prednisone to melphalan (Alkeran) andprednisone (AP), and BCP can be utilized as initial therapy in myel cancer because of comparable remission rates and less hematologic toxicity.
PubMedComparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.
22 Citations1980F Cavagnaro, J M Lein +8 more
The clinical staging system described by Durie and Salmon shows a good prognosis for stage I patients, with 80% remaining alive at 48 months, while the survival curves for stage II and III patients were similar, with 33% and 28% respectively remaining aliveat 48 months.
CancerEffect of sodium fluoride, calcium carbonate, and vitamin D on the skeleton in multiple myeloma
15 Citations1980Robert A. Kyle, Jenifer Jowsey
Administration of sodium fluoride and calcium carbonate produces an increase in bone mass and is a useful adjunct treatment for patients with multiple myeloma.